College of Pharmacy, 37850King Saud University, Riyadh, Saudi Arabia.
J Pharm Pract. 2022 Dec;35(6):971-978. doi: 10.1177/0897190021997399. Epub 2021 Apr 28.
On March 11th, the World Health Organization (WHO) announced the unprecedented outbreak of "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) to be a pandemic. Thus far, COVID-19 has infected over 58,229,138 individuals and caused 1,382,106 deaths worldwide. This has led to the re-purposing of available drugs under "off-label" use-drugs such as hydroxychloroquine and chloroquine. Both drugs have since been evaluated for their ability to treat COVID-19. Here, we summarize recent evidence regarding the use of hydroxychloroquine and chloroquine in hospitalized patients with COVID-19. All data is current as of November 23, 2020.
3 月 11 日，世界卫生组织（WHO）宣布“严重急性呼吸系统综合症冠状病毒 2”（SARS-CoV-2）的爆发为大流行。迄今为止，COVID-19 已感染超过 58229138 人，并在全球范围内造成 1382106 人死亡。这导致了现有药物的重新定位，即“标签外”使用-例如羟氯喹和氯喹。这两种药物此后都被评估了治疗 COVID-19 的能力。在这里，我们总结了最近关于羟氯喹和氯喹在 COVID-19 住院患者中的使用的证据。所有数据均截至 2020 年 11 月 23 日。
